The transplantation of mesenchymal stem cells (MSCs) represents a promising approach for treating the ischemic and the nonischemic diseased heart. The positive effects of transplanting these cells could be shown, but the exact mechanisms remain unknown. We evaluated whether the injection site affects the improvement in left ventricular (LV) ejection fraction (EF) and angiogenesis in doxorubicin (Dox)–induced failing hearts.
Methods
Heart failure was induced in New Zealand white rabbits by doxorubicin treatment, followed by right ventricular MSC transplantation (RV-MSC, n = 6), LV MSC transplantation (LV-MSC, n = 6), sham treatment (sham group, n = 6), or no therapy (Dox group, n = 5). Healthy rabbits were used as control group (n = 8). Cells were isolated after bone marrow aspiration and transplanted locally into the ventricular myocardium. After 4 weeks, cardiac function and capillary density (CD31 staining) were measured.
Results
The transplantation of MSCs increased the EF significantly (LV-MSC, 39.0% ± 1.4%, and RV-MSC, 39.2% ± 2.6%, vs sham group, 29.8% ± 3.7%; P < 0.001), without significance between the MSC groups (P = 0.858). Neither the evidence of a transdifferentiation nor any signs of cell engraftment of transplanted cells could be found. The capillary density (capillaries/high-power field) increased in both MSC groups compared with the sham group (LV-MSC by 8.3% ± 3.4%; and RV-MSC, 8.1% ± 2.2%; P < 0.05), without significance between the two MSC groups (P = 0.927).
Conclusions
Injection of autologous MSCs in doxorubicin-induced cardiomyopathic rabbit hearts improves EF and enhances angiogenesis. Despite local application, we observed global effects on heart function and capillary density without significant difference between right and LV injection. The paracrine mechanism might be one possible explanation for these findings.
TocciG., SciarrettaS., VolpeM.Development of heart failure in recent hypertension trials. J Hypertens.2008; 26: 1477–1486.
2.
BleuminkG.S., KnetschA.M., SturkenboomM.C.Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J.2004; 25: 1614–1619.
3.
ChristieJ.D., EdwardsL.B., KucheryavayaA.Y.The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report—2010. J Heart Lung Transplant.2010; 29: 1104–1118.
4.
SchächingerV., ErbsS., ElsässerA., for the REPAIR-AMI Investigators. Intracoronary bone marrow–derived progenitor cells in acute myocardial infarction. N Engl J Med.2006; 355: 1210–1221.
5.
LundeK., SolheimS., AakhusS., ArnesenH., AbdelnoorM., ForfangK., for the ASTAMI Investigators. Autologous stem cell transplantation in acute myocardial infarction: the ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects. Scand Cardiovasc J.2005; 39: 150–158.
6.
SchaeferA., MeyerG.P., FuchsM.Impact of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: results from the BOOST trial. Eur Heart J.2006; 27: 929–935.
7.
PokushalovE., RomanovA., ChernyavskyA.Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure: a randomized study. J Cardiovasc Transl Res.2010; 3: 160–168.
8.
StrauerB.E., BrehmM., ZeusT.Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation.2002; 106: 1913–1918.
9.
AssmusB., SchächingerV., TeupeC.Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation.2002; 106: 3009–3017.
10.
HamanoK., NishidaM., HirataK.Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: clinical trial and preliminary results. Jpn Circ J.2001; 65: 845–847.
GaliñanesM., LoubaniM., DaviesJ., ChinD., PasiJ., BellP.R.Autotransplantation of unmanipulated bone marrow into scarred myocardium is safe and enhances cardiac function in humans. Cell Transplant.2004; 13: 7–13.
13.
MeyerG.P., WollertK.C., LotzJ.Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J.2009; 30: 2978–2984.
14.
BeitnesJ.O., HoppE., LundeK.Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study. Heart.2009; 95: 1983–1989.
15.
AssmusB., RolfA., ErbsS., for the REPAIR-AMI Investigators. Clinical outcome 2 years after intracoronary administration of bone marrow–derived progenitor cells in acute myocardial infarction. Circ Heart Fail.2010; 3: 89–96.
16.
LiS.H., LaiT.Y., SunZ.Tracking cardiac engraftment and distribution of implanted bone marrow cells: comparing intra-aortic, intravenous, and intramyocardial delivery. J Thorac Cardiovasc Surg.2009; 137: 1225–1233.
17.
MurryC.E., SoonpaaM.H., ReineckeH.Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature.2004; 428: 664–668.
LinkeA., MüllerP., NurzynskaD.Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci U S A.2005; 102: 8966–8971.
20.
KocherA.A., SchusterM.D., SzabolcsM.J.Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med.2001; 7: 430–436.
21.
KubalC., ShethK., Nadal-GinardB., GaliñanesM.Bone marrow cells have a potent anti-ischemic effect against myocardial cell death in humans. J Thorac Cardiovasc Surg.2006; 132: 1112–1118.
22.
TomitaS., LiR.K., WeiselR.D.Autologous transplantation of bone marrow cells improves damaged heart function. Circulation.1999; 100(suppl): II247–II256.
23.
AgbulutO., MenotM.L., LiZ.Temporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy. Cardiovasc Res.2003; 58: 451–459.
24.
GarbadeJ., DheinS., LipinskiC.Bone marrow–derived stem cells attenuate impaired contractility and enhance capillary density in a rabbit model of Doxorubicin-induced failing hearts. J Card Surg.2009; 24: 591–599.
25.
Fischer-RasokatU., AssmusB., SeegerF.H.A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circ Heart Fail.2009; 2: 417–423.
26.
ChenY., LiuW., LiW., GaoC.Autologous bone marrow mesenchymal cell transplantation improves left ventricular function in a rabbit model of dilated cardiomyopathy. Exp Mol Pathol.2010; 88: 311–315.
27.
NagayaN., KangawaK., ItohT.Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation.2005; 112: 1128–1135.
28.
SuzukiK., MurtuzaB., SuzukiN., SmolenskiR.T., YacoubM.H.Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure. Circulation.2001; 104(suppl 1): I213–I217.
29.
SussmanM.A., MurryC.E.Bones of contention: marrow-derived cells in myocardial regeneration. J Mol Cell Cardiol.2008; 44: 950–953.
BehfarA., YamadaS., Crespo-DiazR.Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol.2010; 56: 721–734.
32.
LuC., AraiM., MisaoY.Autologous bone marrow cell transplantation improves left ventricular function in rabbit hearts with cardiomyopathy via myocardial regeneration-unrelated mechanisms. Heart Vessels.2006; 21: 180–187.
33.
Alvarez-DoladoM., PardalR., Garcia-VerdugoJ.M.Fusion of bone-marrow–derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature.2003; 425: 968–973.
34.
HosodaT., ZhengH., Cabral-da-SilvaM.Human cardiac stem cell differentiation is regulated by a mircrine mechanism. Circulation.2011; 123: 1287–1296.
35.
RoeskeF., SteinA., SalamehA.Activation of cardiomyocytes depending on their proximity to human bone marrow stem cells. Thorac Cardiovasc Surg.2011; 59: 78–84.
36.
FazelS., CiminiM., ChenL.Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest.2006; 116: 1865–1877.
37.
KinnairdT., StabileE., BurnettM.S.Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation.2004; 109: 1543–1549.
38.
WinterE.M., van OorschotA.A., HogersB.A new direction for cardiac regeneration therapy: application of synergistically acting epicardium-derived cells and cardiomyocyte progenitor cells. Circ Heart Fail.2009; 2: 643–653.
ArsalanM., WoitekF., AdamsV.Distribution of cardiac stem cells in the human heart. ISRN Cardiol.2012; 2012: 483407. doi: 10.5402/2012/483407.
42.
GnecchiM., HeH., NoiseuxN.Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J.2006; 20: 661–669.
43.
FarahmandP., LaiT.Y., WeiselR.D.Skeletal myoblasts preserve remote matrix architecture and global function when implanted early or late after coronary ligation into infarcted or remote myocardium. Circulation.2008; 118(suppl): S130–S137.
44.
YooK.J., LiR.K., WeiselR.D., MickleD.A., LiG., YauT.M.Autologous smooth muscle cell transplantation improved heart function in dilated cardiomyopathy. Ann Thorac Surg.2000; 70: 859–865.
45.
YooK.J., LiR.K., WeiselR.D.Heart cell transplantation improves heart function in dilated cardiomyopathic hamsters. Circulation.2000; 102: III204–III209.
